Bic

Weak Q3 and a profit warning; turnaround plan awaited

29/10/25 -"Bic’s Q3FY25 results were in line but accompanied by a profit warning and lower guidance. All regions declined, with the US and Mexico being the weakest, and shavers underperforming the most. ..."

PDF page sample
Pages
56
Language
English
Published on
29/10/25
Download
You may also be interested by these reports :
30/10/25
Haleon’s Q3 sales aligned with expectations, driven by growth in Oral Health, VMS, Pain Relief, and Digestive Health. This was partially offset by ...
30/10/25
Essity delivered a profit beat for Q3 2025, with an Adj. EBITA of SEK 5,056m and an impressive 14.6% margin, exceeding consensus despite in-line net ...
29/10/25
Reckitt delivered estimate-beating Q3 2025 sales of £3.61bn, up a robust 7.0%, driven by sequential volume improvements and solid emerging markets ...
29/10/25
Bic’s Q3FY25 results were in line but accompanied by a profit warning and lower guidance. All regions declined, with the US and Mexico being the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO